Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [3][4] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [3] - Insmed's early-stage programs include various technologies such as gene therapy, AI-driven protein engineering, and synthetic rescue [3] Upcoming Event - Management will present at the 2025 Goldman Sachs Annual Global Healthcare Conference on June 11, 2025, at 9:20 a.m. ET [1] - The event will be webcast live and available for 30 days post-event on the company's investor relations website [2]

—    Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE®, TPIP and Health Economics and Outcomes Research   —BRIDGEWATER, N.J., May 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, wh ...

Insmed (INSM) 2025 Conference May 13, 2025 05:20 PM ET Speaker0 Five Healthcare Conference in Las Vegas. My name is Jason Zemanski. I'm one of the SMID cap analysts here at the bank. Joining me on stage is my associate Cameron Bozdag, and I'm very pleased to be sharing the stage here with Will Lewis, chair and CEO of Insmed. Thank you for joining us. Thank you for having me. Absolutely. So a lot to talk about, but I think most investors right now are concentrated on a phase two asset of yours, TPIP. PAH dat ...

Insmed (INSM) reported a first-quarter 2025 loss of $1.42 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.36. In the year-ago quarter, the company posted a loss of $1.06 per share.The company generated total quarterly revenues of $92.8 million, which rose 23% year over year. Quarterly sales were in line with the Zacks Consensus Estimate. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)INSM Stock’s PerformanceShares of the company were down 4% yesterday, l ...

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.41%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.15 per share when it actually produced a loss of $1.32, delivering a ...

Insmed (INSM) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Bryan Dunn - Vice President, Head of Investor RelationsWilliam Lewis - Chair and Chief Executive OfficerSara Bonstein - CFOJason Zemansky - Vice President, Equity Research, Biotechnology and PharmaceuticalsMartina Flammer - Chief Medical OfficerJoseph Schwartz - Senior Managing DirectorDaniel Krizay - VP - Biotech Equity ResearchJennifer Kim - Equity Research DirectorLiisa Bayko - Managing DirectorGraig Suvannavejh - Managing ...

Insmed (INSM) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Thank you for standing by. My name is Amy, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Insmed First Quarter twenty twenty five Financial Results Call. All participants have been placed in a listen only mode. After the speakers' remarks, we will conduct a question and answer session. It is now my pleasure to turn the call over to Brian Dunn. You may begin. Speaker1 Thank you, Amy. ...

May 8, 2025 First-Quarter 2025 Earnings Presentation 1 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates ...

Exhibit 99.1 Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdictio ...